Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Deferred Tax: 2018-2019

Historic Long-Term Deferred Tax for Protagonist Therapeutics (PTGX) over the last 2 years, with Dec 2019 value amounting to $1.4 million.

  • Protagonist Therapeutics' Long-Term Deferred Tax rose 126.36% to $1.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.1 million, marking a year-over-year increase of 126.36%. This contributed to the annual value of $1.4 million for FY2019, which is 117.78% up from last year.
  • According to the latest figures from FY2019, Protagonist Therapeutics' Long-Term Deferred Tax is $1.4 million, which was up 117.78% from $658,000 recorded in FY2018.
  • Protagonist Therapeutics' Long-Term Deferred Tax's 5-year high stood at $1.4 million during FY2019, with a 5-year trough of $658,000 in FY2018.
  • For the 2-year period, Protagonist Therapeutics' Long-Term Deferred Tax averaged around $1.0 million, with its median value being $1.0 million (2018).
  • Data for Protagonist Therapeutics' Long-Term Deferred Tax shows a peak YoY skyrocketed of 117.78% (in 2019) over the last 5 years.
  • Over the past 2 years, Protagonist Therapeutics' Long-Term Deferred Tax (Yearly) stood at $658,000 in 2018, then skyrocketed by 117.78% to $1.4 million in 2019.